Randall A. Oyer, MD
A patient who has a strong reaction to an oncology medication over the weekend and cannot reach their practice may be able to obtain care at an emergency department (ED) but might rack up unnecessary costs and receive inappropriate care from a physician who isn’t aware of their treatment regimen or implications for adverse events. That ED visit might also disrupt the care metrics that the oncology practice relies on to meet increasing standards for value-based care and payment incentives and penalties. Growing awareness of this situation is prompting a revolution in vigilance and attention to detail that has significance both for the quality of care and financial health of practices.
“When I talk to oncologists around the country, everyone is in a new cost consciousness,” said Randall A. Oyer, MD, medical director of the Ann B. Barshinger Cancer Institute at Penn Medicine Lancaster General Health and president-elect of the Association of Community Cancer Centers (ACCC). “Everyone understands the imperative of being good stewards of resources.”
The results of a recent ACCC survey offered a glimpse into how community oncology centers are affected by payers, government, and industry and are leveraging these challenges to come out ahead.1
... to read the full story